Semaglutide for Helping Opioid Recovery

Ki vehet részt

• English-speaking adults aged 18 or older
• DSM-5 diagnosis of severe opioid use disorder (OUD)
• Receiving buprenorphine ≥16 mg/day or methadone ≥70 mg/day for at least 30 days prior to enrollment
• Planning to continue buprenorphine or methadone treatment throughout the study
• Willing to bring buprenorphine prescriptions to visits for dose counts (if applicable)
• Willing to authorize communication between the study team and their MOUD prescriber via a 42 CFR release

Ki nem vehet részt

• Anticipated participation in another investigational drug trial
• Active psychosis, suicidality, homicidality, or psychiatric conditions impairing capacity to consent
• Current or lifetime history of an eating disorder
• Current or lifetime diagnosis of Type 1 or Type 2 diabetes
• Personal or family history of medullary thyroid carcinoma or MEN2
• Myocardial infarction, stroke, unstable angina, or congestive heart failure within the past 90 days
• History of inflammatory bowel disease, bariatric surgery, idiopathic pancreatitis, or diabetic gastroparesis
• History of hypersensitivity or allergy to semaglutide
• Any other condition that investigators determine may interfere with participation or pose a safety concern
• Liver function tests >3x the upper limit of normal or eGFR <30
• BMI <21 kg/m²
• GLP-1 receptor agonist use within the past 3 months or anticipated use during the study
• Persistently elevated BP (>160 mmHg systolic or >100 mmHg diastolic) during screening
• Pregnancy or breastfeeding